Precigen, Inc. (PGEN) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Precigen’s revenue went from $191M in fiscal 2016 to $10M in fiscal 2025, a decline of about 28.2% a year.
Net income in fiscal 2025 was -$251M, a net margin of -2588.2%; the best year in this period was 2022 with $28M.
Over the twelve months to September 30, 2026, revenue was $157M and net income $24M.
Free cash flow was -$90M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 165% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $157M | $10M | $4M | $6M | $27M | $14M | $32M | $91M | $151M | $231M | $191M |
| Gross profit | — | — | — | — | — | — | — | — | — | $198M | $153M |
| Operating income | $34M | -$111M | -$135M | -$100M | — | — | — | -$213M | -$506M | -$138M | -$125M |
| Net income | $24M | -$251M | -$126M | -$96M | $28M | -$92M | -$171M | -$322M | -$509M | -$117M | -$187M |
| EPS (diluted) | $0.10 | $-1.37 | $-0.47 | $-0.39 | $0.14 | $-0.47 | $-1.02 | $-2.09 | $-3.93 | $-0.98 | $-1.58 |
| R&D | $27M | $41M | $53M | $49M | — | — | — | — | $405M | $143M | $112M |
| Revenue growth | — | +146.7% | −37.0% | −76.9% | +88.6% | −55.4% | −64.7% | −40.0% | −34.5% | +21.0% | +10.0% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$73M | -$88M | -$68M | -$67M | -$65M | -$56M | -$77M | -$136M | -$124M | -$104M | -$49M |
| Capital spending | -$1M | -$2M | -$9M | -$2M | -$5M | -$7M | -$8M | -$38M | -$42M | -$47M | -$32M |
| Free cash flow | -$74M | -$90M | -$77M | -$68M | -$70M | -$63M | -$85M | -$174M | -$166M | -$150M | -$81M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $13M | $11M | $9M | $10M | $10M | $14M | $18M | $19M | $36M | $42M | $42M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $98M | $98M | $63M | $56M | $109M | $100M | $75M | $216M | $74M | $237M |
| Debt | — | $98M | $6M | $7M | $51M | $191M | $182M | $246M | $212M | $8M | $8M |
| Equity | — | $21M | $39M | $118M | $126M | $107M | $67M | $72M | $363M | $534M | $560M |
| Total assets | — | $156M | $145M | $151M | $216M | $360M | $315M | $456M | $716M | $847M | $949M |
| Shares (diluted) | 421M | 313M | 268M | 245M | 200M | 198M | 167M | 154M | 130M | 120M | 118M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | — | 85.6% | 80.2% |
| Operating margin | 21.4% | -1141.1% | -3440.2% | -1602.5% | — | — | — | -235.3% | -334.4% | -59.7% | -65.6% |
| Net margin | 15.6% | -2588.2% | -3216.2% | -1540.6% | 105.2% | -646.0% | -533.0% | -355.3% | -336.9% | -50.7% | -97.7% |
| FCF margin | -47.4% | -927.6% | -1955.6% | -1099.9% | -260.0% | -441.7% | -264.3% | -191.6% | -109.7% | -65.1% | -42.2% |
| ROIC | — | -73.2% | -302.5% | -79.0% | — | — | — | -66.8% | -84.6% | -20.1% | -21.6% |
| ROE | — | -1198.6% | -327.8% | -80.9% | 22.4% | -85.9% | -253.8% | -449.5% | -140.4% | -21.9% | -33.3% |
Frequently asked questions
What is Precigen’s annual revenue?
$10M in fiscal 2025 and $157M over the twelve months to September 30, 2026.
How much profit does Precigen make?
Net income was -$251M in fiscal 2025 (net margin -2588.2%).
Is Precigen’s revenue growing?
Yes: revenue rose 146.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.